Skip to main content

Advertisement

SpringerLink
Log in

Regional Radiochemotherapy Using In Situ Hydrogel

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose.

To evaluate the feasibility of regional radiochemotherapy of mammary tumors using in situ hydrogel loaded with cisplatin (CDDP) and rhenium-188 (188Re).

Methods.

Sodium alginate (SA) and calcium chloride were used to create a hydrogel for delivery of CDDP and 188Re. In vitro studies were performed to evaluate cytotoxic effects of 188Re-hydrogel and sustained-release ability of the CDDP-hydrogel. Tumor-bearing rats were injected with 188Re-hydrogel (0.5–1 mCi/rat), 188Re-perrhenate (0.5–1 mCi/rat, intratumoral, I.T.), CDDP-hydrogel (3 mg/kg), and 188Re-hydrogel loaded with CDDP (3 mg/kg body weight, 0.5–1 mCi/rat), respectively, and groups receiving 188Re were imaged at 24 and 48 h postinjection. Tumor volume, body weight, imaging, and kidney function were assessed as required for each group.

Results.

Successful formation of the hydrogel was demonstrated by cytotoxic effects of 188Re-hydrogel and slow release of CDDP-hydrogel in vitro. Tumor volume measurements showed significant delay in tumor growth in treated vs. control groups with minimal variation in normal kidney function for the CDDP-hydrogel group. Scintigraphic images indicated localization of 188Re-hydrogel in the tumor site up to 48 h postinjection.

Conclusions.

Our data demonstrate the feasibility of using hydrogel for delivery of chemotherapeutics and radiation locally. This technique may have applications involving other contrast modalities as well as treatment in cases where tumors are inoperable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CDDP:

cisplatin

IRT:

internal radiation therapy

SA:

sodium alginate

XRT:

radiation therapy

References

  1. 1. B. Marples, O. Greco, M. C. Joiner, and S. D. Scott. Molecular approaches to chemo-radiotherapy. Eur. J. Cancer 38:231–239 (2002).

    Article  CAS  PubMed  Google Scholar 

  2. 2. R. Nath. New directions in radionuclide sources for brachytherapy. Semin. Radiat. Oncol. 3:278–289 (1993).

    PubMed  Google Scholar 

  3. 3. C. Mathew, M. A. Majali, and S. A. Balakrishnan. A novel approach for the adsorption of iodine-125 on silver wire as matrix for brachytherapy source for the treatment of eye and prostate cancer. Appl. Radiat. Isot. 57:359–367 (2002).

    Article  CAS  PubMed  Google Scholar 

  4. 4. G. L. Denardo, S. J. Kennel, J. A. Siegel, and S. J. Denardo. Radiometals as payloads for radioimmunotherapy for lymphoma. Clin. Lymphoma 5(Suppl 1):S5–S10 (2004).

    CAS  PubMed  Google Scholar 

  5. 5. A. O. Schaffland, F. Buchegger, M. Kosinski, C. Antonescu, C. Paschoud, C. Grannavel, R. Pellikka, and A. B. Delaloye. 131I-Rituximab: relationship between immunoreactivity and specific activity. J. Nucl. Med. 45:1784–1790 (2004).

    PubMed  Google Scholar 

  6. 6. Y. Li, Z. Tian, S. M. Rizvi, N. H. Bander, and B. J. Allen. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis. 5:36–46 (2002).

    CAS  PubMed  Google Scholar 

  7. 7. Z. Yao, M. Zhang, K. Garmestani, D. B. Axworthy, R. W. Mallett, A. R. Fritzberg, L. J. Theodore, P. S. Plascjak, W. C. Eckelman, T. A. Waldmann, I. Pastan, C. H. Paik, M. W. Brechbiel, and J. A. Carrasquillo. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′-tetraacetic acid-biotin. Clin. Cancer Res. 10:3137–3146 (2004).

    CAS  PubMed  Google Scholar 

  8. 8. S. Kinuya, K. Yokoyama, M. Izumo, T. Sorita, T. Obata, H. Mori, K. Shiba, N. Watanabe, N. Shuke, T. Michigishi, and N. Tonami. Feasibility of 186Re-radioimmunotherapy for treatment in an adjuvant setting of colon cancer. J. Cancer Res. Clin. Oncol. 129:392–396 (2003).

    Article  CAS  PubMed  Google Scholar 

  9. 9. S. J. DeNardo, L. E. Williams, B. R. Leigh, and R. L. Wahl. Choosing an optimal radioimmunotherapy dose for clinical response. Cancer 94:1275–1286 (2002).

    CAS  PubMed  Google Scholar 

  10. 10. D. Fisher, D. Rajon, H. Breitz, M. Goris, W. Bolch, and S. Knox. Dosimetry model for radioactivity localized to intestinal mucosa. Cancer Biother. Radiopharm. 19:293–307 (2004).

    Article  CAS  PubMed  Google Scholar 

  11. 11. G. A. Wiseman, B. R. Leigh, W. D. Erwin, R. B. Sparks, D. A. Podoloff, R. J. Schilder, N. L. Bartlett, S. M. Spies, A. J. Grillo-Lopez, T. E. Witzig, and C. A. White. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin’s lymphoma and mild thrombocytopenia. Cancer Biother. Radiopharm. 18:165–178 (2003).

    CAS  PubMed  Google Scholar 

  12. 12. I. Novak-Hoferand P. A. Schubiger. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur. J. Nucl. Med. Mol. Imaging 29:821–830 (2002).

    PubMed  Google Scholar 

  13. 13. A. B. Delaloye, B. Delaloye, F. Buchegger, C. A. Vogel, M. Gillet, J. P. Mach, A. Smith, and P. A. Schubiger. Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors. J. Nucl. Med. 38:847–853 (1997).

    CAS  PubMed  Google Scholar 

  14. 14. S. C. Srivastava, H. L. Atkins, G. T. Krishnamurthy, I. Zanzi, E. B. Silberstein, G. Meinken, L. F. Mausner, F. Swailem, T. D’Alessandro, C. J. Cabahug, Y. Lau, T. Park, and S. Madajewicz. Treatment of metastatic bone pain with tin-117m Stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study. Clin. Cancer Res. 4:61–68 (1998).

    CAS  PubMed  Google Scholar 

  15. 15. J. E. Bugaj, J. L. Erion, M. A. Johnson, M. A. Schmidt, and A. Srinivasan. Radiotherapeutic efficacy of (153)Sm-CMDTPA-Tyr(3)-octreotate in tumor-bearing rats. Nucl. Med. Biol. 28:327–334 (2001).

    CAS  PubMed  Google Scholar 

  16. 16. D. J. Kwekkeboom, W. H. Bakker, P. P. Kooij, M. W. Konijnenberg, A. Srinivasan, J. L. Erion, M. A. Schmidt, J. L. Bugaj, M. de Jong, and E. P. Krenning. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur. J. Nucl. Med. 28:1319–1325 (2001).

    CAS  PubMed  Google Scholar 

  17. 17. N. Iznaga-Escobar, I. L. Ramirez, J. C. Izquierdo, L. Suarez, D. Morales, and R. Perez-Rodriguez. 188Re-labeled anti-epidermal growth factor receptor humanized monoclonal antibody h-R3: labeling conditions, in vitro and in vivo stability. Methods Find. Exp. Clin. Pharmacol. 25:703–711 (2003).

    CAS  PubMed  Google Scholar 

  18. 18. T. Y. Luo, B. T. Hsieh, S. J. Wang, W. Y. Lin, T. W. Lee, L. H. Shen, and M. J. Su. Preparation and biodistribution of rhenium-188 ECD/Lipiodol in rats following hepatic arterial injection. Nucl. Med. Biol. 31:671–677 (2004).

    CAS  PubMed  Google Scholar 

  19. 19. H. Zhang, M. Tian, S. Li, J. Liu, S. Tanada, and K. Endo. Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. Cancer Biother. Radiopharm. 18:719–726 (2003).

    CAS  PubMed  Google Scholar 

  20. 20. S. N. Reske, D. Bunjes, I. Buchmann, U. Seitz, G. Glatting, B. Neumaier, J. Kotzerke, A. Buck, H. Martin, H. Dohner, and L. Bergmann. Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation. Eur. J. Nucl. Med. 28:807–815 (2001).

    CAS  PubMed  Google Scholar 

  21. 21. M. Wohlfrom, J. Kotzerke, J. Kamenz, M. Eble, B. Hess, J. Wohrle, S. N. Reske, V. Hombach, H. Hanke, and M. Hoher. Endovascular irradiation with the liquid beta-emitter Rhenium-188 to reduce restenosis after experimental wall injury. Cardiovasc. Res. 49:169–176 (2001).

    CAS  PubMed  Google Scholar 

  22. 22. E. Dadachova, A. Nakouzi, R. A. Bryan, and A. Casadevall. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc. Natl. Acad. Sci. USA 100:10942–10947 (2003).

    CAS  PubMed  Google Scholar 

  23. 23. E. Dadachova, B. Bouzahzah, L. S. Zuckier, and R. G. Pestell. Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl. Med. Biol. 29:13–18 (2002).

    CAS  PubMed  Google Scholar 

  24. 24. J. Scheffler, M. Derejko, T. Bandurski, and G. Romanowicz. Application of rhenium-188 HEDP in bone metastases therapy. Nucl. Med. Rev. Cent. East. Eur. 6:55–57 (2003).

    PubMed  Google Scholar 

  25. 25. L. Nobs, F. Buchegger, R. Gurny, and E. Allemann. Current methods for attaching targeting ligands to liposomes and nanoparticles. J. Pharm. Sci. 93:1980–1992 (2004).

    CAS  PubMed  Google Scholar 

  26. 26. T. Minko, S. S. Dharap, R. I. Pakunlu, and Y. Wang. Molecular targeting of drug delivery systems to cancer. Curr. Drug Targets 5:389–406 (2004).

    CAS  PubMed  Google Scholar 

  27. 27. R. Mehvar. Recent trends in the use of polysaccharides for improved delivery of therapeutic agents: pharmacokinetic and pharmacodynamic perspectives. Curr. Pharm. Biotechnol. 4:283–302 (2003).

    CAS  PubMed  Google Scholar 

  28. 28. Y. Luoand G. D. Prestwich. Cancer-targeted polymeric drugs. Curr. Cancer Drug Targets 2:209–226 (2002).

    PubMed  Google Scholar 

  29. 29. A. Colombo, J. Drzewiecki, A. Banning, E. Grube, K. Hauptmann, S. Silber, D. Dudek, S. Fort, F. Schiele, K. Zmudka, G. Guagliumi, and M. E. Russell. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108:788–794 (2003).

    CAS  PubMed  Google Scholar 

  30. 30. M. Konishi, Y. Tabata, M. Kariya, A. Suzuki, M. Mandai, K. Nanbu, K. Takakura, and S. Fujii. In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel. J. Control. Rel. 92:301–313 (2003).

    CAS  Google Scholar 

  31. 31. J. Blanchette, N. Kavimandan, and N. A. Peppas. Principles of transmucosal delivery of therapeutic agents. Biomed. Pharmacother. 58:142–151 (2004).

    CAS  PubMed  Google Scholar 

  32. 32. M. Ozeki, T. Ishii, Y. Hirano, and Y. Tabata. Controlled release of hepatocyte growth factor from gelatin hydrogels based on hydrogel degradation. J. Drug Target. 9:461–471 (2001).

    CAS  PubMed  Google Scholar 

  33. 33. X. Qu and J. Weinberger. Deposition of (90)YPO(4) and (144)CePO(4) radioisotopes on polymer surfaces for radiation delivery devices. J. Biomed. Mater. Res. 63:98–105 (2002).

    CAS  PubMed  Google Scholar 

  34. 34. X. Qu and J. Weinberger. Encapsulation of isotope on novel beta-emitting poly(ethylene terephthalate) surfaces. J. Biomed. Mater. Res. 57:619–623 (2001).

    CAS  PubMed  Google Scholar 

  35. 35. H. H. Tonnesen and J. Karlsen. Alginate in drug delivery systems. Drug Dev. Ind. Pharm. 28:621–630 (2002).

    CAS  PubMed  Google Scholar 

  36. 36. K. Matsuoka, M. Watanabe, and F. Toriyama. In vitro analysis for cellular toxicity of polychlorinated biphenys (PCBs) on HeLa cellular proliferation (IV)--the effect of Kanpo preparations on cellular toxicity. Fukuoka Igaku Zasshi 88:207–210 (1997).

    CAS  PubMed  Google Scholar 

  37. 37. E. J. Kim, S. G. Sampathkumar, M. B. Jones, J. K. Rhee, G. Baskaran, S. Goon, and K. J. Yarema. Characterization of the metabolic flux and apoptotic effects of O-hydroxyl- and N-acyl-modified N-acetylmannosamine analogs in Jurkat cells. J. Biol. Chem. 279:18342–18352 (2004).

    CAS  PubMed  Google Scholar 

  38. 38. D. J. Yang, C. G. Kim, N. R. Schechter, A. Azhdarinia, D. F. Yu, C. S. Oh, J. L. Bryant, J. J. Won, E. E. Kim, and D. A. Podoloff. Imaging with 99mTc ECDG targeted at the multifunctional glucose transport system: feasibility study with rodents. Radiology 226:465–473 (2003).

    PubMed  Google Scholar 

  39. 39. K. H. Bouhadir, E. Alsberg, and D. J. Mooney. Hydrogels for combination delivery of antineoplastic agents. Biomaterials 22:2625–2633 (2001).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Diagnostic Imaging, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA

    Ali Azhdarinia, David J. Yang, Dong-Fang Yu, Richard Mendez, Changsok Oh, Saady Kohanim, Jerry Bryant & E. Edmund Kim

Authors
  1. Ali Azhdarinia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dong-Fang Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard Mendez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Changsok Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Saady Kohanim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jerry Bryant
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. Edmund Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ali Azhdarinia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Azhdarinia, A., Yang, D., Yu, DF. et al. Regional Radiochemotherapy Using In Situ Hydrogel. Pharm Res 22, 776–783 (2005). https://doi.org/10.1007/s11095-005-2594-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-005-2594-7

Key Words:

Search

Navigation